[an error occurred while processing this directive]
综述

慢性肾衰竭血管钙化骨标志物的研究进展

  • 廖晟淳 ,
  • 叶朝阳
展开
  • 201203 上海,1上海中医药大学附属曙光医院肾病科 上海中医药大学中医肾病研究所

收稿日期: 2023-05-23

  修回日期: 2023-06-05

  网络出版日期: 2023-08-12

基金资助

国家自然科学基金面上项目(82170747);华东片区及市级中医专科专病联盟建设项目-肾水病中医专病联盟建设[ZY(2021-2023)-0302]

Advances in the study of bone markers for vascular calcification in chronic renal failure patients 

  • LIAO Sheng-Chun ,
  • YE Chao-Yang
Expand
  • Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Institute of Traditional Chinese Medicine Kidney Disease, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received date: 2023-05-23

  Revised date: 2023-06-05

  Online published: 2023-08-12

摘要

慢性肾脏病(chronic kidney disease,CKD)-矿物质和骨异常(mineral and bone disorder,MBD)引发的血管钙化(vascular calcification,VC)导致了CKD患者的高心血管死亡率,是CKD重要的临床并发症。骨标志物可观测或参与到VC的过程,对VC的防治起到重要作用。本文将对VC的发生机制进行深入学习,并对常见的骨标志物如甲状旁腺激素(PTH)-25羟维生素D(25-VitD)-成纤维细胞生长因子23(FGF23)-Klotho间的相互反馈影响、骨钙素(osteocalcin,OCN)、I型胶原羧基端肽β特殊序列(carboxy-terminal peptide β special sequence,β-CTX)、总Ⅰ型胶原氨基端延长肽(total type I collagen amino-terminal extension peptide,tP1NP)及研究进展做一综述。

本文引用格式

廖晟淳 , 叶朝阳 . 慢性肾衰竭血管钙化骨标志物的研究进展[J]. 中国血液净化, 2023 , 22(08) : 608 -611 . DOI: 10.3969/j.issn.1671-4091.2023.08.009

Abstract

Vascular calcification (VC) caused by chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important clinical complication, and contributes to the higher cardiovascular mortality in CKD patients. Bone markers can be detected or even involved in the process of VC. Bone markers play important roles in the study of VC. In this paper, we provide an in-depth study of the mechanism of VC, and review the mutual feedback effects among common bone markers such as parathyroid hormone, 25-hydroxyvitamin D, fibroblast growth factor 23 and Klotho (PTH-25OHVitD-FGF23-Klotho). We also summarize the recent research progresses in osteocalcin (OCN), type I collagen carboxy-terminal peptide β special sequence (β-CTX), and total type I collagen amino-terminal extension peptide (tP1NP).

参考文献

[1] Singh, Anubha, Tandon, et al. An update on vascular calcification and potential therapeutics.
[2] 陈荣,李怡,王莉.慢性肾脏病VC诊治进展[J].实用医院临床杂志,2022,19(02):183-186.
[3] Kerstin B , Karl-Friedrich H , Christoph D , et al. Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation[J]. International Journal of Nephrology, 2018, 2018:1-7.
[4] Liu ZH, Yu XQ, Yang JW, et al. Prevalence and risk factors for vascularcalcification in Chinese patients receiving dialysis: baseline results from aprospective cohort study. Curr Med Res Opin, 2018, 34(8): 1491-1500
[5] Singh, Anubha, Tandon, et al. An update on vascular calcification and potential therapeutics.
[6] 马清华, 刘玉秀, 申红远,等. VC的调控因子[J]. 中华老年心脑血管病杂志, 2015.
[7] Shroff R , Long D A , Shanahan C . Mechanistic Insights into Vascular Calcification in CKD[J]. Journal of the American Society of Nephrology Jasn, 2013, 24(2):179-189.
[8] Vahed S Z , Mostafavi S , Khatibi S , et al. Vascular Calcification: An Important Understanding in Nephrology[J]. Vascular Health and Risk Management, 2020, Volume 16:167-180.
[9] Sun J L , Lee I K , Jeon J H . Vascular Calcification—New Insights into Its Mechanism[J]. International Journal of Molecular Sciences, 2020, 21(8).
[10] Himmelsbach A , Ciliox C , Goettsch C . Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities[J]. Toxins, 2020, 12(3).
[11] Waziri B, Duarte R, Naicker S. Chronic kidney disease–mineral and bone disorder (CKD-MBD): current perspectives[J]. International journal of nephrology and renovascular disease, 2019, 12: 263.
[12] 兰天鹰, 叶朝阳, 姚东升,等. 123例维持性血液透析患者矿物质及骨代谢水平的调查分析[J]. 临床肾脏病杂志, 2018, 18(8):5.
[13] Carrillo-López Natalia, Sara P , Cristina A M , et al. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease[J]. Nephrology Dialysis Transplantation(6):6.
[14] Jeffrey W , Jimmy Z , Graham R , et al. Vitamin D in Vascular Calcification: A Double-Edged Sword?[J]. Nutrients, 2018, 10(5):652.
[15] Cui Q . Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation[J]. Endocrinology, 2020, 161(1):pii: bqz025.
[16] 杨枫,林评兰,邹赟,等. Klotho在慢性肾脏病血管钙化中作用的研究进展[J]. 中国血液净化,2021,20(3):189-192. DOI:10.3969/j.issn.1671-4091.2021.03.010.
[17] Cianciolo G, Galassi A, Capelli I, et al. Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white?[J]. Current vascular pharmacology, 2018, 16(2): 143-156.
[18] Ignacio C P ,Petra S . PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: Genetics, epigenetics and beyond [J]. Frontiers in Endocrinology,2022,13.
[19] Kuro-o M. The Klotho proteins in health and disease[J]. Nature Reviews Nephrology, 2019, 15(1): 27-44.
[20] Carrillo-López N ,Martínez-Arias L ,Fernández-Villabrille S , et al. Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders[J]. Calcified Tissue International,2021,108(4).
[21] Chen Y X, Huang C, Duan Z B, et al. Klotho/FGF23 axis mediates high phosphate‐induced vascular calcification in vascular smooth muscle cells via Wnt7b/β‐catenin pathway[J]. The Kaohsiung Journal of Medical Sciences, 2019, 35(7): 393-400.
[22] Wu Q, Fan W, Zhong X, et al. Klotho/FGF23 and Wnt in SHPT associated with CKD via regulating miR-29a[J]. American Journal of Translational Research, 2022, 14(2): 876.
[23] Komori T . What is the function of osteocalcin?[J]. Journal of Oral Biosciences, 2020, 62(3).
[24] Namba S , Yamaoka-Tojo M , Hashikata T , et al. Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis[J]. BBA Clinical, 2015.
[25] Chi P J, Lin Y L, Tasi J P, et al. Osteocalcin and carotid–femoral pulse wave velocity in patients on peritoneal dialysis[J]. Tzu-Chi Medical Journal, 2019, 31(1): 23.
[26] Millar S A , Hinal P , Anderson S I , et al. Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis[J]. Frontiers in Endocrinology, 2017, 8:183.
[27] Yeap B B , Chubb S , Flicker L , et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study[J]. Osteoporosis International, 2012.
[28] E, Lerchbaum, V, et al. Association of bone turnover markers with mortality in men referred to coronary angiography[J]. Osteoporosis International, 2013.
[29] Ning F L , Tao J , Li D D , et al. Activating BK channels ameliorates vascular smooth muscle calcification through Akt signaling[J]. Acta Pharmacologica Sinica.
[30] Luo F , Guo W , Liu W . Exosomes derived from bone marrow mesenchymal stem cells inhibit human aortic vascular smooth muscle cells calcification via the miR-15a/15b/16/NFATc3/OCN axis[J]. Biochemical and biophysical research communications, 2022, 635:65-76.
[31] Dai L , Debowska M , Lukaszuk T , et al. Phenotypic features of vascular calcification in chronic kidney disease[J]. Journal of Internal Medicine, 2020, 287.
[32] Yang Z K , Ying C , Zhao H Y , et al. Mineral metabolism disturbances are associated with the presence and severity of calcific aortic valve disease[J]. 浙江大学学报B辑(生物医学与生物技术)(英文版), 2015.
[33] Jasna A , Samantha K , Mirna V D , et al. Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis[J]. Bone, 2018, 113:118-123.
[34] Deluccia R , Cheung M , Ramadoss R , et al. The Endocrine Role of Bone in Cardiometabolic Health[J]. Current Nutrition Reports, 2019, 8(1).
[35] Cavalier E , Lukas P , Carlisi A , et al. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters.[J]. CLINICA CHIMICA ACTA, 2013.
[36] Diemar S S , Dahl S S , West A S , et al. A Systematic Review of the Circadian Rhythm of Bone Markers in Blood[J]. Calcified Tissue International, 2022:1-22.
文章导航

/

[an error occurred while processing this directive]